“With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout within our existing cash runway,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio (BOLD).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLD:
- Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
- Boundless Bio announces FDA accepted IND application of BBI-940
- Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
- Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know